Clinical trials: Prostate Disease
Prostate Cancer
Androcur Effects on Quality of Life
Androcur is an antiandrogenic drug, which blocks the action of male sex hormones. Androcur is used for treatment of advanced prostate cancer.
- Trial name
- NCT00908674
- Testing
- Cyproterone acetate (Androcur)
- Where
- Hungary
- Volunteers
- 245 people
- Sponsor
- Bayer
Prostate Cancer
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel, and to see whether adding AS1404 and docetaxel together improves the outcome of the treatment, when compared to docetaxel alone.
- Trial name
- NCT00111618
- Testing
- AS1404 (DMXAA)
- Where
- 27 sites in United States
- Volunteers
- 70 people
- Sponsor
- Antisoma Research
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Benign Prostatic Hyperplasia
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects
- Trial name
- NCT07444385
- Testing
- AD-116, AD-1161
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a…
- Trial name
- NCT02123758
- Testing
- Abiraterone Acetate, Prednisone, JNJ-56021927
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 57 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Pancreatic Neoplasms, Ovarian Neoplasms
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
This is a phase 1, Open-label, multicenter Dose Escalation study of BTP-114, a novel platinum product, in patients with advanced solid tumors and BRCA or other DNA repair mutation.
- Conditions
- Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT02950064
- Testing
- BTP-114
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- Placon Therapeutics
Prostate Cancer
Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer
The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry of HRS-9815 for PET/CT imaging in adult patients with prostate cancer.
- Trial name
- NCT06062355
- Testing
- HRS-9815 injection
- Volunteers
- 9 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Prostatic Hyperplasia
Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate.
- Trial name
- NCT00116571
- Testing
- Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
- Where
- 9 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- QLT Inc.
Prostate Cancer
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004071
- Testing
- leflunomide, mitoxantrone hydrochloride, prednisone
- Where
- 3 sites in United States
- Sponsor
- Pfizer
Prostatic Neoplasms
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory…
- Trial name
- NCT00031187
- Testing
- SGN-15 (cBR96-doxorubicin immunoconjugate), Taxotere (docetaxel)
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- Seagen Inc.
Benign Prostatic Hyperplasia
Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter
The purpose of this study is to evaluate the efficacy and safety of dutasteride at reducing relapse rates of Acute Urinary Retention (AUR), including reduction in surgical intervention for benign prostatic hyperplasia (BPH), in…
- Trial name
- NCT00421421
- Testing
- Dutasteride
- Where
- 25 sites in United Kingdom
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline
Castration-Resistant Prostate Cancer
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
- Trial name
- AFFIRM (NCT00974311)
- Testing
- Enzalutamide
- Where
- 249 sites in United States, Argentina and 13 more
- Volunteers
- 1,199 people
- Sponsor
- Pfizer
Prostatic Neoplasms
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT)…
- Trial name
- NCT02531516
- Testing
- Apalutamide, Bicalutamide, GnRH (agonist)
- Where
- 263 sites in United States, Argentina and 21 more
- Volunteers
- 1,503 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC
This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in subjects with mCRPC. Phase 1 of the study will be a single-arm dose escalation study of EPI-7386 in combination with a fixed dose of…
- Trial name
- NCT05075577
- Testing
- Enzalutamide, EPI-7386 with Enzalutamide
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 77 people
- Sponsor
- ESSA Pharmaceuticals
Prostate Cancer, Prostatic Cancer
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms
- Trial name
- NCT00643617
- Testing
- CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk
- Where
- 18 sites in United States
- Volunteers
- 307 people
- Sponsor
- Accuray Incorporated
Prostate Cancer
Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
The study will be conducted in 2 Stages. The primary objective of Stage 1 of the study is to identify the maximum tolerated dose (MTD) of ES414 administered intravenously to patients with mCRPC.
- Trial name
- NCT02262910
- Testing
- ES414
- Where
- 7 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Aptevo Therapeutics
Prostate Cancer
Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device
The purpose of this study is to evaluate the effectiveness of Focal-Fusion Bx at detecting clinically significant prostate cancer in a standard clinical environment.
- Trial name
- NCT02524860
- Testing
- Focal-Fusion Bx
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Focal Healthcare Inc.
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Prostate Cancer
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation
- Trial name
- PRIME (NCT07146113)
- Where
- 16 sites in Russia
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.